JB Chemicals & Pharmaceuticals’ (JBCPL) Q2FY24 revenue growth of 8.9% was impacted by discontinuation of low margin tender business in South Africa (annual hit of INR 1.2bn) and slowdown in acute therapies. However, traction in chronic therapies (up 14%) and CMO business helped it deliver better than (our) expected margins and PAT.